Descrizione

Examination of the SIRT1 signaling axis in melatonin-treated prostate cancer cells. SIRT1 activation by MLT appears to mediate epigenetic changes that influence CES1 expression.

Figure 10

Chart

Source Paper

Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.

Clinical and translational medicine (2021)

PMID: 34185414

DOI: 10.1002/ctm2.449

Cite This Figure

![Figure 10: Examination of the SIRT1 signaling axis in melatonin-treated prostate cancer cells. SIRT1 activation by MLT appears to mediate epigenetic changes that influence CES1 expression.]()

> Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." *Clinical and translational medicine*, 2021. PMID: [34185414](https://pubmed.ncbi.nlm.nih.gov/34185414/)

<figure>
  <img src="" alt="Examination of the SIRT1 signaling axis in melatonin-treated prostate cancer cells. SIRT1 activation by MLT appears to mediate epigenetic changes that influence CES1 expression." />
  <figcaption>Figure 10. Examination of the SIRT1 signaling axis in melatonin-treated prostate cancer cells. SIRT1 activation by MLT appears to mediate epigenetic changes that influence CES1 expression.<br>  Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." <em>Clinical and translational medicine</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34185414/">34185414</a></figcaption>
</figure>

Evidenze correlate

Melatonin per Disturbo del ritmo circadiano

Grado A · 176 studi